- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana-Farber Cancer Institute | Strategic Alliance Partners
Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Latest from Dana-Farber Cancer Institute
Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma
May 02, 2024
Article
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Dr Bellmunt on the Impact of Treatment With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer
May 02, 2024
Video
Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.
Dr Anderson on the FDA ODAC Decision Regarding Cilta-Cel in R/R Multiple Myeloma
April 29, 2024
Video
Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.
More Than 25% of Cancer Survivors Report Significant Levels of Disability After Cancer Diagnosis, According to New Study
April 25, 2024
Article
A survey of cancer survivors found that over a quarter had a physical disability impairing mobility and almost 10% had a disability affecting self-care.
ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy
April 25, 2024
Article
Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.
Study Provides a First Look at Oncologists' Views on Ethical Implications of AI in Cancer Care
April 19, 2024
Article
In a survey, over 200 oncologists agreed on how AI can be responsibly integrated into patient care and how to protect patients from hidden biases of AI.
Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma
April 18, 2024
Article
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
April 17, 2024
Article
Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.
Dana-Farber Cancer Institute Earns Fifth Consecutive Magnet® Designation Recognizing Excellence in Nursing Practice and Patient Care
April 15, 2024
Article
The American Nurses Credentialing Center has awarded Magnet® status to Dana-Farber Cancer Institute for the 5th time in a row.
Dr Park on the Initial Efficacy of Epacadostat Plus Preoperative Chemoradiation in Rectal Cancer
April 11, 2024
Video
Haeseong Park, MD, MPH, discusses phase 1 results of epacadostat plus preoperative chemoradiation in locally advanced rectal cancer.
Insider Insights: Unveiling Takeaways from AACR 2024
April 11, 2024
Article
Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.
Dr Brown on the Potential for Pirtobrutinib to Address Treatment Discontinuation in CLL
April 09, 2024
Video
Jennifer R. Brown, MD, PhD, discusses how pirtobrutinib may address BTK inhibitor discontinuation in chronic lymphocytic leukemia.
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer
April 08, 2024
Video
Rebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.
Neuro-Inclusive Oncology Care and Empowerment Program
April 08, 2024
Article
Dana-Farber details how their Neuro-Inclusive Oncology Care and Empowerment program was developed to help physicians and other providers treat cancer in patients who have intellectual and/or developmental disabilities.
Dr Xu on Ongoing Biomarker Research in Metastatic RCC
April 05, 2024
Video
Wenxin (Vincent) Xu, MD, discusses ongoing efforts to identify new biomarkers in metastatic renal cell carcinoma.
Scott Armstrong Named Senior Vice President for Drug Discovery and Chief Research Strategy Officer at Dana-Farber
April 02, 2024
Article
Scott Armstrong, MD, PhD, has been named senior vice president for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute.
Ongoing Trials Aim to Build on Systemic Therapy Combinations in Advanced RCC
April 01, 2024
Article
Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.
Establishing Biomarkers Is Key to Driving Personalized Systemic Treatment Choices in Advanced RCC
March 30, 2024
Article
Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.
Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
March 28, 2024
Podcast
Dr Wagner discusses unmet needs for patients with PEComa, ongoing research to address these gaps, and findings from the AMPECT trial.